Inquis Medical announced it closed a $75 million Series C financing to accelerate nationwide commercial expansion of its AVENTUS thrombectomy system and advance a next-generation product pipeline, as the company looks to scale adoption in venous thromboembolic disease (VTE).
The Menlo Park, California-based medical device company said the round was funded by an undisclosed strategic investor and follows what it described as a “transformative” 2025 in which it transitioned into a commercial-stage organization after a national launch of AVENTUS.
Inquis said recent milestones included expanded regulatory clearance for pulmonary embolism (PE) and publication of pivotal clinical data in the Journal of the Society for Cardiovascular Angiography & Interventions. The company said the published results showed significant thrombus removal while minimizing blood loss through integrated autologous blood reinfusion in 130 intermediate-risk PE patients, with no device-related adverse events reported.
The Series C follows Inquis Medical’s $40 million Series B financing completed in August 2024, which the company said was led by Marshall Wace.
Inquis plans to use the new capital to grow its commercial footprint by expanding sales and physician-training infrastructure, while continuing to build its clinical evidence base and progress its innovation roadmap.
AVENTUS is designed to address procedural complexities in thrombectomy, including PE interventions, by enabling directional aspiration with in-line blood reinfusion intended to improve clot removal efficiency while reducing blood loss and procedural complexity, the company said. Inquis added that the platform’s proprietary tissue-sensing technology provides real-time feedback to help operators differentiate between blood, clot, and vessel wall, supported by an atraumatic dilator tip and an integrated navigation catheter.
Founded in 2020, Inquis Medical focuses on mechanical thrombectomy for VTE, including pulmonary embolism and deep vein thrombosis, with AVENTUS positioned as its flagship system.
KEY QUOTES:
“The successful closing of our Series C financing marks a pivotal inflection point for Inquis Medical as we scale our footprint in the VTE market. This partnership with a strategic investor provides the capital necessary to execute our long-term vision of redefining the standard of care in VTE through the convergence of clinical excellence and technological innovation.”
Vahid Saadat, Co-Founder and Co-CEO of Inquis Medical
“This capital infusion is a strong endorsement of our commercial trajectory and the clinical progress our team has achieved. With this investment, we are well positioned to scale our market presence and advance our innovation roadmap, ensuring physicians have access to advanced tools to improve outcomes in VTE care.”
Mojgan Saadat, Co-Founder and Co-CEO of Inquis Medical
